News

Default rates are hitting recent highs, and internal reviews of loan health point to tougher times ahead, a WSJ analysis shows.

(Bloomberg) -- Latigo Biotherapeutics Inc., a clinical-stage developer of non-opioid pain medicines, climbed 17% on Friday after raising $345.6 million in an upsized initial public offering, priced at the top of a marketed range.Most Read from BloombergOpenAI’s New Device Will Be Hockey Puck-Sized and Cost Over $300Iran Wants to Bar US, Israeli Ships From Hormuz in Peace AccordIran Says Agreement on Hormuz Shipping Reached With OmanTrump Administration Considers Order on Autism and VaccinesWhy D

Wall Street's major market averages were mixed in late-morning trading Thursday, as investors reacte

(Bloomberg) -- Blue Owl Capital Inc. is in advanced talks to buy a minority stake of the NBA’s Cleveland Cavaliers, according to people familiar with the matter. Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetGrand Ole Opry House Up For Sale by Owner Ryman HospitalityStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapMicron Soars After AI-Fueled Forecast Shatters EstimatesStocks Climb Late After Micron’s Blowout Outlook: Markets WrapThe transa

(Bloomberg) -- Blue Owl Capital is preparing to launch a debut credit secondaries strategy and is in early-stage talks with prospective investors for the fund, according to a person familiar with the matter.Most Read from BloombergUS Has Opened a Passage Through Hormuz, Central Command SaysDOJ Plans Intervention in Trump Supreme Court Carroll AppealBillionaire Duke of Westminster to Sell £700 Million of US Real Estate AssetsChina Asks Banks to Pause New Loans to US-Sanctioned RefinerSony to Pay